ストックスクリーナーアプリを入手
5.16
2.79%
0.14
アフターアワーズ：
5.16
前日終値:
$5.02
開ける：
$5.08
24時間の取引高:
278.78K
Relative Volume:
1.65
時価総額：
$196.27M
収益：
$239.40M
当期純損益:
$104.44M
株価収益率:
1.7432
EPS:
2.96
ネットキャッシュフロー:
$-18.50M
1週間 パフォーマンス:
-11.49%
1か月 パフォーマンス:
-21.22%
6か月 パフォーマンス:
-59.34%
1年 パフォーマンス:
-63.69%
1日の値動き範囲:
$5.03
$5.19
1週間の範囲:
$4.93
$5.98
52週間の値動き範囲:
$4.93
$21.79
Entrada Therapeutics Inc Stock (TRDA) Company Profile
名前
Entrada Therapeutics Inc
セクター
電話
857-305-1825
住所
ONE DESIGN CENTER PLACE, BOSTON
TRDA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TRDA
Entrada Therapeutics Inc
|
5.16 | 190.95M | 239.40M | 104.44M | -18.50M | 2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-06 | 開始されました | ROTH MKM | Buy |
| 2024-01-05 | 開始されました | Oppenheimer | Outperform |
| 2023-04-03 | 開始されました | H.C. Wainwright | Buy |
Entrada Therapeutics Inc (TRDA) 最新ニュース
Entrada Therapeutics Inc. recovery potential after sell offFree Long Hold Safe Return Strategy - Newser
Is Entrada Therapeutics Inc. stock reversal real or fakeAI Trend Detection for Entry Timing - Newser
Tools to assess Entrada Therapeutics Inc.’s risk profileFree Access to Smart Investment Tips - Newser
Real time breakdown of Entrada Therapeutics Inc. stock performanceWeekly Chart-Based Forecast for Traders - Newser
Is Entrada Therapeutics Inc. meeting your algorithmic filter criteriaSmart Stock Forecast Using AI Algorithms - Newser
What makes Entrada Therapeutics Inc. stock price move sharplyTrading Opportunities Forecast by AI Insight - Newser
Applying chart zones and confluence areas to Entrada Therapeutics Inc.Swing Entry Risk Mitigation with Chart Analysis - Newser
Measuring Entrada Therapeutics Inc.’s beta against major indicesBuy and Hold Position Summary Review - Newser
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Analysts Just Slashed This Year's Estimates - 富途牛牛
HC Wainwright Issues Pessimistic Outlook for TRDA Earnings - Defense World
Roth Capital Issues Pessimistic Forecast for TRDA Earnings - Defense World
Why Entrada Therapeutics Inc. stock attracts strong analyst attentionWeekly Market Direction and Sector Summary - Newser
William Blair Issues Negative Forecast for TRDA Earnings - Defense World
Is Entrada Therapeutics Inc. stock bottoming outFree AI Screening for Swing Trade Picks - Newser
Entrada Therapeutics' Revenue Estimates Cut by 57% Amid Weaker Q1 Results - AInvest
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - simplywall.st
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Analysts Are Cutting Their Estimates: Here's What You Need To Know - uk.finance.yahoo.com
Entrada Therapeutics (NASDAQ:TRDA) Downgraded to Sell Rating by Wall Street Zen - Defense World
Live market analysis of Entrada Therapeutics Inc.Market Stability and Long-Term Growth Outlook - Newser
Sentiment analysis tools applied to Entrada Therapeutics Inc.Algorithmic Forecast for Swing Trading Picks - Newser
Roth/MKM lowers Entrada Therapeutics stock price target to $17 from $21 - Investing.com Canada
Buy Rating for Entrada Therapeutics: Strong Pipeline and Financial Stability Amidst DMD Advancements - TipRanks
Entrada Therapeutics Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Entrada (TRDA) Q2 Revenue Drops 98% - AOL.com
Entrada Therapeutics 2025 Q2 Earnings Misses Targets with Net Loss Widens 178.3% - AInvest
Entrada Therapeutics Reports Q2 2025 Financial Results - TipRanks
Entrada Therapeutics Q2 Revenue Falls 98%, Losses Widen to $1.04 per Share - AInvest
Entrada (TRDA) Q2 Revenue Drops 98% - The Motley Fool
Entrada Therapeutics shares fall 1.01% after-hours after reporting a net loss of USD 43.1 million for Q2 2025. - AInvest
Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Lags Revenue Estimates - sharewise.com
Entrada Therapeutics Reports Q2 Loss, Misses Revenue Estimates, Shares Down 66.3% YTD - AInvest
Entrada Therapeutics August 2025 slides: advancing four clinical-stage programs - Investing.com Canada
Entrada Therapeutics earnings missed by $0.22, revenue fell short of estimates - Investing.com Canada
Entrada Therapeutics, Inc. SEC 10-Q Report - TradingView
Entrada Therapeutics Q2 collaboration revenue drops, net loss widens - MarketScreener
Entrada Therapeutics Reports Second Quarter 2025 Financial Results - Stock Titan
Promising Clinical Developments and Strategic Pipeline Expansion Support Buy Rating for Entrada Therapeutics - TipRanks
Can volume confirm reversal in Entrada Therapeutics Inc.Pattern Recognition Based Market Move Prediction - Newser
Pattern Scan Adds Entrada Therapeutics Inc. to WatchlistTrade Timing Strategy With Technical Data Explained - metal.it
Entrada Therapeutics Inc (TRDA) 財務データ
収益
当期純利益
現金流量
EPS
0.91%
3.06%
大文字化:
|
ボリューム (24 時間):